Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 dec 2005 - 08:17
Statutaire naam
Crucell N.V.
Titel
Crucell and DSM further strengthen and expand the development of PER.C6® Protein and Monoclonal Antibody Licensing Business
Bericht
Joint R&D center to be established on US East Coast and in the Netherlands
Leiden/Heerlen, The Netherlands, December 20, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products (a business group of Royal DSM NV) announced today that they will strengthen and expand the development of the PER.C6® protein and monoclonal antibody licensing business. The two companies will create an integrated solution for the production of recombinant proteins and monoclonal antibodies on PER.C6® in order to increase licensing and royalty income and accelerate the development and roll-out of the PER.C6® technology platform in the market.
Datum laatste update: 10 januari 2026